TEVNF (TEVNF) Stock Price & Analysis
TEVNF (TEVNF) rose 0.00% to USD 0 as of June 10, 2026 at 12:09 UTC, according to Nexqual real-time market data.
TEVNF last closed at USD 0; the session ranged USD 0–0 on volume of 3,000 shares. Market capitalization is $300, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 12:09 UTC.
Key Statistics (as of June 10, 2026 at 12:09 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 3,000 shares |
| Market Cap | $300 |
| Exchange | PNK |
Technical Analysis (TEVNF)
Nexqual's technical model rates TEVNF "SELL" based on 0 bullish and 1 bearish signals across 124 daily candles, as of June 10, 2026 at 12:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 0) |
Analyst Ratings (TEVNF)
Wall Street analysts rate TEVNF "None", per Nexqual as of June 10, 2026 at 12:09 UTC.
| Consensus Rating | None |
|---|
Earnings (TEVNF)
Source: Nexqual, June 10, 2026 at 12:09 UTC.
Financials & Fundamentals (TEVNF)
| Total Revenue | $2,175 |
|---|---|
| Gross Margin | -92.05% |
| Operating Margin | -180831.63% |
| Profit Margin | +0.00% |
| Current Ratio | 0.04 |
| Total Cash | $74,408 |
| Total Debt | $59,401 |
| Free Cash Flow | $-1.96M |
Source: Nexqual, June 10, 2026 at 12:09 UTC.
Financial Health Score (TEVNF)
Nexqual rates TEVNF's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:09 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $74K cash, no debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Mixed — No data |
Ownership (TEVNF)
| Insider Ownership | +6.45% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 30.03M |
| Float | 50.69M |
Source: Nexqual, June 10, 2026 at 12:09 UTC.
Leadership (TEVNF)
TEVNF is led by John Benjamin Sawchuk, Interim CEO, Interim CFO & Chairman of the Board, per Nexqual as of June 10, 2026 at 12:09 UTC.
| Interim CEO, Interim CFO & Chairman of the Board | John Benjamin Sawchuk |
|---|---|
| Chief Technology Officer | Dusty Mckinnon |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GMVDF | G Medical Innovations Holdings | USD 0 | ▲ 0% |
| NMTRQ | 9 Meters Biopharma, Inc. | USD 0 | ▲ 0% |
| BRSF | BRAIN SCIENTIFIC INC | USD 0 | ▲ 0% |
| TBBA | TEB Bancorp Inc. | USD 6.5 | ▼ 0.31% |
| BDRLQ | Blonder Tongue Laboratories, In | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:09 UTC. This page is informational and not investment advice.